The price of Axcella Health Inc. (NASDAQ:AXLA) shares last traded on Wall Street fell -3.81% to $0.60.
Based on available information, 1 analysts follow Axcella Health Inc. (NASDAQ:AXLA). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $1.50 and a low of $1.50, we find $1.50. Given the previous closing price of $0.62, this indicates a potential upside of 141.94 percent. AXLA stock price is now 99.12% away from the 50-day moving average and 39.02% away from the 200-day moving average. The market capitalization of the company currently stands at $71.55M.
Among analysts, 1 rate the stock a hold while 0 rate it a buy. Brokers who have rated the stock have averaged $1.50 as their price target over the next twelve months.
With the price target of $6, Noble Capital Markets recently initiated with Outperform rating for Axcella Health Inc. (NASDAQ: AXLA).
In other news, Koziel Margaret, Chief Medical Officer sold 679 shares of the company’s stock on Mar 01. The stock was sold for $394 at an average price of $0.58. Upon completion of the transaction, the Chief Medical Officer now directly owns 24,883 shares in the company, valued at $14929.8. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 19, President & CEO Hinshaw William sold 16,000 shares of the business’s stock. A total of $25,027 was realized by selling the stock at an average price of $1.56. This leaves the insider owning 82,012 shares of the company worth $49207.2. Insiders disposed of 16,679 shares of company stock worth roughly $10007.4 over the past 1 year. A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in AXLA stock. A new stake in Axcella Health Inc. shares was purchased by MORGAN STANLEY during the first quarter worth $15,000. PORTSIDE WEALTH GROUP, LLC invested $7,000 in shares of AXLA during the first quarter. In total, there are 35 active investors with 46.60% ownership of the company’s stock.
A candlestick chart of Axcella Health Inc. (NASDAQ: AXLA) showed a price of $0.6300 on Monday morning. During the past 12 months, Axcella Health Inc. has had a low of $0.10 and a high of $2.49. The fifty day moving average price for AXLA is $7.8344 and a two-hundred day moving average price translates $10.2700 for the stock.
The latest earnings results from Axcella Health Inc. (NASDAQ: AXLA) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.05, beating analysts’ expectations of -$0.06 by 0.01. This compares to -$0.40 EPS in the same period last year. The company reported revenue of $3.54 million for the quarter, compared to $20.62 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -82.82 percent.
Axcella Health Inc.(AXLA) Company Profile
Axcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.
